I feel I must reply to a comment from @DavidRelman in a recent @nytimes article on a piece of mine in @ScienceMagazine on why a careful analysis of the earliest known cases in Wuhan indicate that the pandemic started at the Huanan Market.
“It is based on fragmentary information and to a large degree, hearsay,” David A. Relman, a professor of microbiology at Stanford University, said... “In general, there is no way of verifying much of what he describes, and then concludes.”
Here is the article, for those who would like to test David's dismissals against what I actually present in the piece. I do hope you'll do so.

science.org/doi/10.1126/sc…
I am concerned about anti-scientific comments like this that reflect a desire to downplay, denigrate, or dismiss evidence that doesn't suit the desires of advocates of a particular hypothesis (in David's case, the lab leak hypothesis).
There is enough of this sort of "I'll-believe-what-I-want-to-believe-in-the-face-of-all-evidence-to-the-contrary" going around these days for it not to leak further into scientific discourse.
More concerning is a strain of bias, also present in other leading proponents of lab leak scenarios such as @Ayjchan, where first-hand comments by Chinese doctors, scientists and, apparently COVID-19 patients, are easily and dismissed as lies or, here, "hearsay".
The strength of my article is that it draws on firsthand accounts - including audio/video recordings - of doctors, hospital administrators and patients like Zhang Jixian, Xia Wenguang, Wei Guixian, Chen Honggang, Ai Fen and Yuan Yufeng.
To deride and dismiss the accounts of these individuals as hearsay is beyond disrespectful.

It begs the question, why?
Zhang Jixian, at Hubei Provincial Hospital of Integrated Chinese and Western Medicine, for example, single-handedly worked out on Dec 27 that this was likely a new viral disease, human to human transmissible, with asymptomatic (lack of) presentation.
Is her account of these discoveries, and the soon-to-follow insight that most cases in her hospital were workers at Huanan Market, hearsay?
Are the recorded voices of early patients like Chen Honggang and Wei Jixian not vivid and real enough to be counted by @DavidRelman as non-hearsay evidence?
“In general, there is no way of verifying much of what he describes, and then concludes.”

There is a way: it just involves not dismissing the voices of the frontline workers and COVID patients in Wuhan as dishonest or hopelessly unreliable in recounting their own experiences.
Here is the NYTimes article:

nytimes.com/2021/11/18/hea…
Oh for the ability to edit! It was not in that NYTimes article. It was in this article by @JoelAchenbach
in @washingtonpost:

washingtonpost.com/health/2021/11…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Michael Worobey

Michael Worobey Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MichaelWorobey

18 Nov
I wrote a Perspective on the origin of COVID just released in @ScienceMagazine

science.org/doi/10.1126/sc…
I have spent the last few months trying to poke holes in the hypothesis of a natural origin of SARS-CoV-2 by asking:

Was the apparent preponderance of early cases linked to Huanan Market real or just a mirage because that is where people were looking for cases?
This is a key question, because if the pattern is real, it is *very* hard to explain why we would observe it if the outbreak had not started at the market, in particular the western section where illegal wildlife like raccoon dogs was sold. It's about the size of a Home Depot.
Read 17 tweets
5 Nov
1/11 It's a great day! Pfizer's new SARS-CoV-2 antiviral cuts deaths by about 90%

But it's also a good time for a thread about the evolution of antiviral drug resistance.

apnews.com/article/corona…
2/ In 1987, FDA approved the first HIV antiviral, AZT. Hope quickly turned to despair though, because in patient after patient the virus quickly evolved to become resistant to AZT.

It wasn't until 1996 that the key breakthrough emerged.
3/ At a conference in Vancouver BC, researchers revealed that if patients were given "triple therapy", cocktails of drugs that attacked HIV in different ways, resistance could be averted.
Read 11 tweets
1 Oct
1/ Medium thread on #SARSCoV2's furin cleavage site and a strikingly similar region in some of the new BANAL genomes from Lao, and in RmYN02 from China.

Seems worth trying to clear up the confusion of @ydeigin on this issue (even it means broadcasting my pic, below).
2/ The furin cleavage site of SC2 is the RRAR in the NSPRRAR stretch of amino acids in the alignment I'm holding up there. It is what makes the virus 'pop' in humans.

The BANAL viruses have NSPAAR. A couple other ones, including RmYN02, have NSPAAR or NSPVAR.
3/ So, having barely scratched the surface of the genetic diversity of these viruses in the wild, we've found several that are literally a *single* amino acid away from having a furin cleavage site.

For example: (NSP) ->inserted R<- AAR.
Read 11 tweets
15 Sep
1: A thread connecting the dots between:

(1) @PeterDaszak et al's fascinating recent preprint on the *many* SARS-related CoV infections in humans per year in Southeast Asia, and

(2) The furin cleavage site of SARS-CoV-2, and

(3) Why Wuhan?

medrxiv.org/content/10.110…
2: The study uses a clever combination of data streams to estimate that 400,000 people per year are being infected by SARS-related coronaviruses.
3: The authors note that not all of those infections are likely to be transmissible human to human

I strongly agree with this. We would see multiple new pandemic origins every year if even 0.1% of these were viable human to human pathogens.
Read 15 tweets
4 Sep
1: I want to follow up the thread below with some additional clarification of why we hypothesize that there may be no real #SARSCoV2 genomes transitional between lineages A and B.

2: @daoyu15 has written a thread asserting that we "toss any genomes that don't fit your conclusions away". I'm afraid this is incorrect on multiple counts.

3: What we show is that many of the putatively transitional genomes bear obvious evidence of being artefacts - probably due to bioinformatic pipelines, rather than sequencing errors per se. (Issues like calling a site with poor coverage to be the base of a reference genome.)
Read 13 tweets
4 Sep
1: We have just posted a study suggesting there may be no real #SARSCoV2 genomes that are transitional between lineages A and B. Arcane, right?

But stick with me - this stuff is *absolutely* crucial to figuring out how the pandemic got started.

virological.org/t/evidence-aga…
2: Honoured to be working on this project with an *amazing* team: @jepekar, @EdythParker, Jennifer Havens, @suchard_group, Kristian Andersen, @niemasd, @arambaut, and Joel Wertheim (leading the charge).

So, what's a 'transitional' genome?
3: To explain, let me introduce you to 'lineage A' and 'lineage B', aka 'clade II' and 'clade I', respectively, in this paper by Zhang et al. These lineages co-circulated in China during the early days of the pandemic, and they differ at two key sites.

nature.com/articles/s4158…
Read 33 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Thank you for your support!

Follow Us on Twitter!

:(